Alcon makes final push for WaveLight

Article

Alcon has received all the required regulatory clearances relating to its tender offer for WaveLight AG.

Alcon has received all the required regulatory clearances relating to its tender offer for WaveLight AG.

Upon settlement of all tendered shares, Alcon will own 77.4% of the outstanding WaveLight shares and shareholders who tendered their shares under the offer will automatically receive payment.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.